An acellular pertussis vaccine in healthy adults: Safety and immunogenicity

Vaccine

Volumn 17, Issue 23-24, 1999, Pages 2999-3006

  Rothstein, Edward P ^a,b   Anderson, Edwin L ^c   Decker, Michael D ^d   Poland, Gregory A ^e   Reisinger, Keith S ^f   Blatter, Mark M ^f   Jacobson, Robert M ^e   Mink, Chrisanna M ^c   Gennevois, Daniel ^g   Izu, Allen E ^g   Sinangil, F ^g   Langenberg, Andria G M ^g  

^a Pennridge Pediatric Associates   (United States)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c S Louis Univ Hlth Sciences Center   (United States)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Mayo Vaccine Research Group   (United States)

^f Pittsburgh Pediatric Research   (United States)

^g NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Acellular pertussis vaccine; Adult immunization

Indexed keywords

HEMAGGLUTININ; IMMUNOGLOBULIN G; PERTUSSIS TOXIN; PERTUSSIS VACCINE; SODIUM CHLORIDE;

ADULT; ANIMAL CELL; ANTIBODY TITER; ARTICLE; BORDETELLA PERTUSSIS; CHO CELL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IMMUNOGENICITY; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; NONHUMAN; NORMAL HUMAN; PERTUSSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VACCINATION;

EID: 0033529606     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(99)00164-4     Document Type: Article

References (46)

1. Hinman A.R., Koplan J.P. Pertussis and pertussis vaccine. Reanalysis of benefits, risks, and costs. JAMA. 251:1984;3109-3113.
2. Mortimer E.A. Pertussis vaccines. Plotkin S.A., Mortimer E.A. Vaccines. 2nd ed. 1994;102 W.B. Saunders Co, Philadelphia.
3. Black S.B., Shinefield H.R., Bergen R., Hart C., Kremers R., Lavetter A., Lemesurier J., Morozumi P.A., Ray P., Lewis E.M., Fireman B., Schwalbe J., Hallam P., Shandling M., Dekker C., Granoff D.M., Izu A., Podda A. Safety and immunogenicity of Chiron/Biocine recombinant acellular pertussis-diphtheria-tetanus vaccine in infants and toddlers. Pediatric Infectious Diseases Journal. 16:1997;53-58.
4. Decker M.D., Edwards K.M., Steinhoff M.C., Rennels M.B., Pichichero M.E., Englund J.A., Anderson E.L., Deloria M.A., Reed G.F. Comparison of 13 acellular pertussis vaccines: adverse reactions. Pediatrics. 96:1995;557-566.
5. Podda A., De Luca E.C., Titone L., Casadei A.M., Cascio A., Peppoloni S., Volpini G., Marsili I., Nencioni L., Rappuoli R. Acellular pertussis vaccine composed of genetically inactivated pertussis toxin: safety and immunogenicity in 12- to 24- and 2- to 4-month old children. Journal of Pediatrics. 120:1992;680-685.
6. Edwards K.M., Meade B.D., Decker M.D., Reed G.F., Rennels M.B., Stenhoff M.C., Anderson E.L., Englund J.A., Pichichero M.E., Deloria M.A., Deforest A. Comparison of 13 acellular pertussis vaccines: overview and serologic response. Pediatrics. 96:1995;548-557.
7. Bernstein H.H., Rothstein E.P., Pennridge Pediatric Associates, Pichichero M.E., Green J.L., Reisinger K.S., Blatter M.M., Halpern J., Arbeter A.M., Bernstein D.I., Smith V., Long S.S., Rathfon H., Krause D.S. Reactogenicity and immunogenicity of a three-component acellular pertussis vaccine administered as the primary series to 2, 4 and 6 month old infants in the United States. Vaccine. 13:1995;1631-1635.
8. Greco D., Salmas S., Mastrantonio P., Giuliano M., Tozzi A.E., Anemona A., degli Atti Ciofi M.L., Giammanco A., Panei P., Blackwelder W.C., Klein D.L., Wassilak S.G. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. New England Journal of Medicine. 334:1996;341-348.
9. Olin P., Rasmussen F., Gustafsson L., Hallander H.O., Heijbel H. Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine. Ad Hoc Group for the Study of Pertussis Vaccines. Lancet. 350:1997;1569-1577.
10. Gustafsson L., Hallander H.O., Olin P., Reizenstein E., Storsaeter J. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. New England Journal of Medicine. 334:1996;349-355.
11. Nennig M.E., Shinefield H.R., Edwards K.M., Black S.B., Fireman B.H. Prevalence and incidence of adult pertussis in an urban population. JAMA. 275:1996;1672-1674.
12. Wright S.W., Edwards K.M., Decker M.D., Zeldin M.H. Pertussis infection in adults with persistent cough. JAMA. 273:1995;1044-1046.
13. Mink C.A., Sirota N.M., Nugent S. Outbreak of pertussis in a fully immunized adolescent and adult population. Archives of Pediatric and Adolescent Medicine. 148:1994;153-157.
14. Mink C.M., Cherry J.D., Christenson P., Lewis K., Pineda E., Shilian D., Dawson J.A., Blumberg D.A. A search for Bordetella pertussis infection in university students. Clinical Infectious Diseases. 14:1992;464-471.
15. Robertson P.W., Goldberg H., Jarvie B.H., Smith D.D., Whybin L.R. Bordetella pertussis infection: a cause of persistent cough in adults. Medical Journal of Australia. 146:1987;522-525.
16. Heininger U., Klich K., Stehr K., Cherry J.D. Clinical findings in Bordetella pertussis infections: results of a prospective multicenter surveillance study. Pediatrics. 100:1997;e10.
17. Trollfers B., Rabo E. Whooping cough in adults. British Medical Journal. 283:1981;696-697.
18. Halperin S.A., Marrie T.J. Pertussis encephalopathy in an adult: case report and review. Review of Infectious Diseases. 13:1991;1043-1047.
19. Farizo K.M., Cochi S.L., Zell E.R., Brink E.W., Wassilak S.G., Patriarca P.A. Epidemiological features of pertussis in the United States, 1980-1989. Clinical Infectious Diseases. 14:1992;708-719.
20. Christie C.D., Baltimore R.S. Pertussis in neonates. American Journal of Diseases in Children. 143:1989;1199-1202.
21. Mortimer E.A. Jr. Pertussis and its prevention: a family affair. Journal of Infectious Diseases. 161:1990;473-479.
22. Long S.S., Welkon C.J., Clark J.L. Widespread silent transmission of pertussis in families: antibody correlate of infection and symptomatology. Journal of Infectious Diseases. 161:1990;480-486.
23. Mertsola J., Ruuskanen O., Eerola E., Viljanen M.K. Intrafamilial spread of pertussis. Journal of Pediatrics. 103:1983;359-363.
24. Cherry J.D., Baraff L.J., Hewlett E. The past, present and future of pertussis: the role of adults in epidemiology and future control. Western Journal of Medicine. 150:1989;319-328.
25. Edwards K.M. Acellular pertussis vaccines - A solution to the pertussis problem? Journal of Infectious Diseases. 168:1993;15-20.
26. Cherry J.D. Acellular pertussis vaccines - A solution to the pertussis problem? Journal of Infectious Diseases. 168:1993;21-24.
27. Nencioni L., Pizza M., Bugnoli M., De Magistris T., Di Tommaso A., Giovannoni F., Manetti R., Marsili I., Matteucci G., Nucci D., Oliviere R., Pileri P., Presentini R., Villa L., Kreeftenberg J.G., Silvestri S., Tagliabue A., Rappuoli R. Characterization of genetically inactivated pertussin toxin mutants: candidates for a new vaccine against whooping cough. Infection and Immunity. 58:1990;1308-1315.
28. Cherry J.D., Gornbein J., Heininger U., Stehr K. A search for correlates of immunity to Bordetella pertussis cough illnesses. Vaccine. 16:1998;1901-1906.
29. Storsaeter J., Hallander H.O., Gustafsson L., Olin P. Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine. 16:1998;1907-1916.
30. Podda A., Nencioni L., DeMagistris M.D., Di Tommaso A., Bossu P., Nuti S., Pileri P., Peppoloni S., Bugnoli M., Ruggiero P., Marsili I., D'Errico A., Tagliabue A., Rappuoli R. Metabolic humoral and cellular responses in adult volunteers immunized with the genetically inactivated pertussis toxin mutant PT-9 K/129G. Journal of Experimental Medicine. 172:1990;861-868.
31. Nencioni L., Podda A., Peppoloni S., Volpini G., Marsili I., Contu B., Campus G., Cossu M.A., Vanni R., Silvestri S., Rappuoli R. Evaluation of acellular DTP vaccines in infants. Mem Inst Butantan. 53:1991;21-29.
32. Keitel W., Edwards K., Englund J., Mink C., Blumberg D., Muenz L., Decker M. Dose-response comparisons of 5 acellular pertussis vaccines in healthy adults. Abstracts of the National Institutes of Health Pertussis Conference, June 3-5, Washington, D.C. 1996.
33. Ruuskanen O., Noel A., Putto-Laurila A., Capiau P.C., Delem A., Vandevoorde D., Simoen E., Teuwen D.E., Bogaerts H., André F.E. Development of an acellular pertussis vaccine and its administration as a booster in healthy adults. Vaccine. 9:1991;117-121.
34. Granström M., Thorén M., Tiru M., Sato Y. Acellular pertussis vaccine in adults: adverse reactions and immune response. European Journal of Clinical Microbiology. 6:1987;18-21.
35. Edwards K.M., Decker M.D., Graham B.S., Mezzatesta J., Scott J., Hackell J. Adult immunization with acellular pertussis vaccine. JAMA. 269:1993;53-56.
36. Linnemann C.C., Ramundo N., Perlstein P.H., Minton S.D., Englender G.S. Use of pertussis vaccine in an epidemic involving hospital staff. Lancet. 2:(7934):1975;540-543.
37. Pichichero M.E., Treanor J. Economic impact of pertussis. Archives of Pediatric and Adolescent Medicine. 151:1997;35-40.
38. Cattaneo L.A., Reed G.W., Haase D.H., Wills M.J., Edwards K.M. The seroepidemiology of Bordetella pertussis infections: a study of persons aged 1-65 years. Journal of Infectious Diseases. 173:1996;1256-1259.
39. Cromer B.A., Goydos J., Hackell J., Mezzatesta J., Dekker C., Mortimer E.A. Unrecognized pertussis in adolescents. American Journal of Diseases in Children. 147:1993;575-577.
40. Schmitt-Grohe S., Cherry J.D., Heininger U., Uberall M.A., Pineda E., Stehr K. Pertussis in German adults. Clinical Infectious Diseases. 21:1995;860-866.
41. Weber D.J., Rutala W.A. Management of healthcare workers exposed to pertussis. Infection Control and Hospital Epidemiology. 15:1994;411-415.
42. Aoyama T., Takeuchi Y., Goto A., Iwai H., Murase Y., Iwata T. Pertussis in adults. American Journal of Diseases in Children. 146:1992;163-166.
43. Giuliano M., Mastrantonio P., Giammanco A., Piscitelli A., Salmaso S., Wassilak S.G. Antibody responses and persistence in the two years after immunization with two acellular vaccines and one whole-cell vaccine against pertussis. Journal of Pediatrics. 132:1998;983-988.
44. Di Tommaso A., Bartalini M., Peppoloni S., Podda A., Rappuoli R., De Magistris M.T. Acellular pertussis vaccines containing genetically detoxified pertussis toxin induce long-lasting humoral and cellular responses in adults. Vaccine. 15:1997;1218-1224.
45. American Academy of Pediatrics 1994 Report of the Committee of Infectious Diseases. Red Book 22nd ed.
46. Centers for Disease Control, Prevention. Update on Adult Immunization. Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR. 40:no.RR-12:1991;16-19.